Biogen Inc. (NASDAQ:BIIB) Short Interest Up 15.4% in April

Key Points

• Short interest in Biogen rose 15.4% in April to 4,414,958 shares, equal to about 3.0% of shares and a short‑interest ratio of 3.1 days based on average daily volume.
• Biogen beat Q1 estimates (non‑GAAP EPS $3.57 vs $2.95; revenue $2.48B vs $2.29B) but narrowed FY‑2026 non‑GAAP EPS guidance to $14.25–$15.25 due to acquisition‑related IPR&D and M&A charges, introducing near‑term downside risk.
• Analyst reactions are mixed — several firms raised price targets (e.g., HC Wainwright to $237, RBC to $222) while the Street consensus remains a Hold with a $213.12 average price target.

Biogen Inc. (NASDAQ:BIIB - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 4,414,958 shares, a growth of 15.4% from the March 31st total of 3,826,441 shares. Based on an average trading volume of 1,439,919 shares, the short-interest ratio is currently 3.1 days. Currently, 3.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Barclays began coverage on Biogen in a report on Thursday, February 19th. They issued an "equal weight" rating and a $185.00 price objective for the company. Mizuho upped their price target on shares of Biogen from $207.00 to $236.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. Citigroup decreased their price target on shares of Biogen from $215.00 to $190.00 and set a "neutral" rating for the company in a research note on Monday, April 13th. HC Wainwright raised their price objective on shares of Biogen from $228.00 to $237.00 and gave the stock a "buy" rating in a research report on Thursday, April 2nd. Finally, Argus upgraded shares of Biogen to a "hold" rating in a research note on Thursday, April 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biogen has a consensus rating of "Hold" and a consensus price target of $213.12.

Biogen Price Performance

Biogen stock opened at $189.28 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.03. The business has a 50 day simple moving average of $184.52 and a 200-day simple moving average of $176.06. Biogen has a 12 month low of $115.25 and a 12 month high of $202.41. The stock has a market capitalization of $27.78 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 1.63 and a beta of 0.16.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analysts' expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts predict that Biogen will post 14.91 earnings per share for the current year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat — Biogen reported better‑than‑expected Q1 revenue and EPS (revenue $2.48B; non‑GAAP EPS $3.57), driven by growth-product sales and strong commercial execution, which is a key reason investors pushed the stock higher after results. Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Growth-product tailwinds — Management highlighted in‑market LEQEMBI and SKYCLARYS sales and a Spinraza high‑dose approval; investors view these as sustainable revenue drivers that underpin the beat and longer‑term upside. Biogen shares rise after Q1 earnings beat, growth-product momentum, and pipeline/M&A updates
• Positive Sentiment: Analyst price‑target lifts — Multiple firms raised targets (RBC to $222, HC Wainwright to $237 and TD Cowen $215) and issued Buy/outperform notes, supporting upside prospects and helping offset guidance worries. RBC raises price target to $222 HC Wainwright raises PT to $237
• Neutral Sentiment: BMO keeps Hold — Some analysts remain cautious on near‑term growth and kept neutral/market‑perform ratings (BMO $196 PT), reflecting debate over how quickly new product momentum will offset costs. Biogen kept at Hold by BMO
• Neutral Sentiment: Mixed analyst views — Street reactions range from cautious to bullish; consensus price‑target dispersion is wide, so expect continued volatility as guidance clarity and M&A detail emerge. Analysts’ Opinions Are Mixed
• Negative Sentiment: Guidance trimmed on acquisition charges — Biogen narrowed FY‑2026 non‑GAAP EPS to $14.25–$15.25, citing acquisition‑related IPR&D and other M&A charges tied to business development (Apellis deal impacts), which trimmed some of the upside from the quarter and prompted concern over near‑term earnings. Biogen cuts annual profit forecast on acquisition-related charges (Reuters)
• Negative Sentiment: One‑time M&A costs weigh on outlook — Coverage notes the EPS trim reflects transaction costs rather than core operating weakness, but the cut still creates near‑term downside risk until the strategic rationale and integration benefits are clearer. Biogen beats Q1 but cuts 2026 EPS view (Zacks)

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC raised its stake in shares of Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock worth $965,000 after buying an additional 2,777 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock valued at $1,392,000 after buying an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Biogen during the second quarter worth $216,000. Cerity Partners LLC raised its position in Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company's stock worth $5,847,000 after acquiring an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company's stock worth $336,000 after acquiring an additional 316 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.